These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675 [TBL] [Abstract][Full Text] [Related]
6. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. Jorda A; Zeitlinger M Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355 [No Abstract] [Full Text] [Related]
9. In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria. Yamano Y Clin Infect Dis; 2019 Nov; 69(Suppl 7):S544-S551. PubMed ID: 31724049 [TBL] [Abstract][Full Text] [Related]
10. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176 [TBL] [Abstract][Full Text] [Related]
12. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196 [TBL] [Abstract][Full Text] [Related]
13. Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria. Ong'uti S; Czech M; Robilotti E; Holubar M Clin Infect Dis; 2022 Apr; 74(7):1303-1312. PubMed ID: 34492098 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany. Thelen P; Henriksen AS; Longshaw C; Yamano Y; Caldwell B; Hamprecht A J Glob Antimicrob Resist; 2022 Mar; 28():12-17. PubMed ID: 34920174 [TBL] [Abstract][Full Text] [Related]
18. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE). Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections. Drwiega EN; Griffith NC; Danziger LH Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):245-259. PubMed ID: 35594628 [TBL] [Abstract][Full Text] [Related]
20. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety. Lee YR; Yeo S Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]